The Ross operation: A Trojan horse?
Aims: The Ross operation is the operation of choice for children who require aortic valve replacement (AVR) and may also provide a good option in selected adult patients. Although the autograft does not require anticoagulation and has a superior haemodynamic profile, concern regarding autograft and allograft longevity has risen. In this light, we report the 13-year results of our prospective autograft cohort study. Methods and results: Between 1988 and 2005, 146 consecutive patients underwent AVR with a pulmonary autograft at Erasmus Medical Center Rotterdam. Mean age was 22 years (SD 13; range 4 months-52 years), 66% were male. Hospital mortality was 2.7% (N = 4); during follow-up four more patients died. Thirteen-year survival was 94 ± 2%. Over time, 22 patients required autograft reoperation for progressive neo-aortic root dilatation. In addition, eight patients required allograft reoperation. Freedom from autograft reoperation at 13 years was 69 ± 7%. Freedom from allograft reoperation for structural failure at 13 years was 87 ± 5%. Risk factors for autograft reoperation were previous AVR and adult patient age. Conclusion: Although survival of the Rotterdam autograft cohort is excellent, over time a worrisome increase in reoperation rate is observed. Given the progressive autograft dilatation, careful follow-up of these patients is warranted in the second decade after operation.
|Keywords||Autograft dilatation, Prospective study, Reoperation, Ross operation, Survival|
|Persistent URL||dx.doi.org/10.1093/eurheartj/ehl550, hdl.handle.net/1765/35749|
Klieverik, L.M.A., Takkenberg, J.J.M., Bekkers, J.A., Roos-Hesselink, J.W., Witsenburg, M., & Bogers, A.J.J.C.. (2007). The Ross operation: A Trojan horse?. European Heart Journal, 28(16), 1993–2000. doi:10.1093/eurheartj/ehl550